SCHEMBL3019739

SCHEMBL3019739

Cc1cc(C)cc(-c2csc(N3CCN(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
MAPT P10636 8/20 0.55
USP2 O75604 1/20 0.55
RECQL P46063 1/20 0.55
HSD17B10 Q99714 1/20 0.55
MAPK1 P28482 5/20 0.51
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
LMNA P02545 8/20 0.47
POLB P06746 2/20 0.46
HTT P42858 5/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 4/20 0.43
NPSR1 Q6W5P4 3/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 1/20 0.43
LPAR1 Q92633 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651001 0.97 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3651654 0.94 SMN1; SMN2 (0.57) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3016455 0.92 SMN1; SMN2 (0.67) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3006283 0.91 MAPT (0.61) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3011117 0.91 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3014369 0.91 SMN1; SMN2 (0.64) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3013474 0.90 SMN1; SMN2 (0.66) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3019120 0.90 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3015563 0.90 SMN1; SMN2 (0.69) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3011343 0.89 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.